MS Speaks

A slide show for professionals only is viewable at this BARTS blog Website.

The slide presentation is put out by Biogen Idec and includes the following information about PML:

As of 2/4/14 there have been 439 confirmed cases of PML in Tysabri-treated MS patients. That is an increase of 9 cases compared to January.  As of 12/31/13, there have been 123,000 MS patients who have ever received Tysabri.

The mortality is at 23% (101 MS deaths due to Tysabri-related PML).

There is also this statement:

As of February 4, 2014, the duration of natalizumab dosing prior to PML diagnosis ranged from 8 to 91 doses; approximately 16% had between 1-24 doses and 64% had >24 doses at the time of PML diagnosis.